Breast Disease pp 325-335 | Cite as

Breast Cancer in Older Women

  • Soley Bayraktar
  • Adnan Aydiner


Breast cancer generally develops in older women, and its incidence is continuing to increase with the increasing age of the population. The pathology and biology of breast cancer appear to be different in the elderly, often resulting in the undertreatment of elderly patients and thus in higher rates of recurrence and mortality. The aim of this chapter is to describe the differences in the biology and treatment of early breast cancer in the elderly. Because most breast cancers in the elderly are hormone responsive, hormonal therapy remains the mainstay of systemic treatment in the adjuvant setting. The role of chemotherapy is limited to patients who test negative for hormone receptors and demonstrate an aggressive tumor profile. Although the prognosis of breast cancer patients has generally improved in the last few decades, there is still demand for evidence-based optimization of therapeutic interventions in older patients.


Elderly Breast Cancer Disease management Chemotherapy Trastuzumab 


  1. 1.
    SEER Cancer Statistics Review (CSR) 1975-2014. Available from:
  2. 2.
    de Kruijf EM, Bastiaannet E, Ruberta F, de Craen AJ, Kuppen PJ, Smit VT, et al. Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. Mol Oncol. 2014;8(5):1014–25.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Ebner F, van Ewijk R, Wockel A, Hancke K, Schwentner L, Fink V, et al. Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients. Breast. 2015;24(3):256–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer. 2004;90(8):1486–91.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Angarita FA, Chesney T, Elser C, Mulligan AM, McCready DR, Escallon J. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol. 2015;41(5):625–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985;1(8433):829–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr. 1997;22:27–30.CrossRefGoogle Scholar
  8. 8.
    Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst. 1993;85(20):1644–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Tabar L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260(3):658–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ. 1988;297(6654):943–8.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. Int J Cancer. 1997;70(2):164–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Olmi P, Fallai C, Cerrotta AM, Lozza L, Badii D. Breast cancer in the elderly: the role of adjuvant radiation therapy. Crit Rev Oncol Hematol. 2003;48(2):165–78.PubMedCrossRefGoogle Scholar
  13. 13.
    Molino A, Giovannini M, Auriemma A, Fiorio E, Mercanti A, Mandara M, et al. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol. 2006;59(3):226–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155(8):481–92.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Tew WP, Muss HB, Kimmick GG, Von Gruenigen VE, Lichtman SM. Breast and ovarian cancer in the older woman. J Clin Oncol. 2014;32(24):2553–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Kimmick GG, Muss HB. Systemic therapy for older women with breast cancer. Oncology (Williston Park). 2001;15(3):280–91; discussion 91–2, 95–6, 99.Google Scholar
  17. 17.
    Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008;206(1):66–75.PubMedCrossRefGoogle Scholar
  18. 18.
    Wyld L, Reed M. The role of surgery in the management of older women with breast cancer. Eur J Cancer. 2007;43(15):2253–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Kiderlen M, Bastiaannet E, Walsh PM, Keating NL, Schrodi S, Engel J, et al. Surgical treatment of early stage breast cancer in elderly: an international comparison. Breast Cancer Res Treat. 2012;132(2):675–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Hamaker ME, Bastiaannet E, Evers D, Water W, Smorenburg CH, Maartense E, et al. Omission of surgery in elderly patients with early stage breast cancer. Eur J Cancer. 2013;49(3):545–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Newlin ME, Reiling R, Nichols K. Necessity of axillary dissection in elderly women with early breast cancer. World J Surg. 2002;26(10):1239–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Martelli G, Boracchi P, Orenti A, Lozza L, Maugeri I, Vetrella G, et al. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients. Eur J Surg Oncol. 2014;40(7):805–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Downey L, Livingston R, Stopeck A. Diagnosing and treating breast cancer in elderly women: a call for improved understanding. J Am Geriatr Soc. 2007;55(10):1636–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang J, Kollias J, Boult M, Babidge W, Zorbas HN, Roder D, et al. Patterns of surgical treatment for women with breast cancer in relation to age. Breast J. 2010;16(1):60–5.PubMedCrossRefGoogle Scholar
  27. 27.
    In H, Jiang W, Lipsitz SR, Neville BA, Weeks JC, Greenberg CC. Variation in the utilization of reconstruction following mastectomy in elderly women. Ann Surg Oncol. 2013;20(6):1872–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Crombag MR, Joerger M, Thurlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of selected anticancer drugs in elderly cancer patients: focus on breast cancer. Cancers (Basel). 2016;8(1):6.CrossRefGoogle Scholar
  29. 29.
    van Maaren MC, van Steenbeek CD, Pharoah PDP, Witteveen A, Sonke GS, Strobbe LJA, et al. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. Eur J Cancer. 2017;86:364–72.PubMedCrossRefGoogle Scholar
  30. 30.
    Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658–67.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Muss HB. Adjuvant chemotherapy in older women with breast cancer: who and what? J Clin Oncol. 2014;32(19):1996–2000.PubMedCrossRefGoogle Scholar
  32. 32.
    Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefGoogle Scholar
  33. 33.
    Jones EL, Leak A, Muss HB. Adjuvant therapy of breast cancer in women 70 years of age and older: tough decisions, high stakes. Oncology (Williston Park). 2012;26(9):793–801.Google Scholar
  34. 34.
    Early Breast Cancer Trialists’ Collaborative Group, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.CrossRefGoogle Scholar
  35. 35.
    Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177–83.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25(24):3699–704.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kummel S, et al. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat. 2015;152(2):377–87.PubMedCrossRefGoogle Scholar
  41. 41.
    Loibl S, von Minckwitz G, Untch M, Denkert C, German Breast G. Predictive factors for response to neoadjuvant therapy in breast cancer. Oncol Res Treat. 2014;37(10):563–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Halfter K, Ditsch N, Kolberg HC, Fischer H, Hauzenberger T, von Koch FE, et al. Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study. BMC Cancer. 2015;15:519.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2018;167(1):59–71.PubMedCrossRefGoogle Scholar
  44. 44.
    Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors associated with early mortality among patients with de novo metastatic breast cancer: a population-based study. Oncologist. 2017;22(4):386–93.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Robson M, Goessl C, Domchek S. Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med. 2017;377(18):1792–3.PubMedCrossRefGoogle Scholar
  47. 47.
    Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.CrossRefGoogle Scholar
  48. 48.
    Tarantini L, Gori S, Faggiano P, Pulignano G, Simoncini E, Tuccia F, et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012;23(12):3058–63.PubMedCrossRefGoogle Scholar
  49. 49.
    Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A, et al. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. Oncologist. 2013;18(7):795–801.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Du XL, Xia R, Burau K, Liu CC. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol. 2011;28(Suppl 1):S80–90.PubMedCrossRefGoogle Scholar
  51. 51.
    Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31(33):4222–8.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Dall P, Lenzen G, Gohler T, Lerchenmuller C, Feisel-Schwickardi G, Koch T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: results from an observational study in Germany. J Geriatr Oncol. 2015;6(6):462–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021–8.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–41.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol. 2011;41(5):709–12.PubMedCrossRefGoogle Scholar
  56. 56.
    Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Goss PE, Smith IE, O’Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(1):88–96.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Denegri A, Moccetti T, Moccetti M, Spallarossa P, Brunelli C, Ameri P. Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol. 2016;13(4):355–63.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL. The consequence of undertreating breast cancer in the elderly. J Am Coll Surg. 2001;192(6):698–707.PubMedCrossRefGoogle Scholar
  60. 60.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRefGoogle Scholar
  61. 61.
    Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–802.PubMedCrossRefGoogle Scholar
  63. 63.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–92.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29(9):1117–24.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Breast International Group 1-98 Collaborative Group, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.CrossRefGoogle Scholar
  66. 66.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802–10.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–46.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Laenkholm AV, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst. 2011;103(18):1363–72.PubMedCrossRefGoogle Scholar
  70. 70.
    Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494–502.PubMedCrossRefGoogle Scholar
  71. 71.
    Markopoulos C, van de Water W. Older patients with breast cancer: is there bias in the treatment they receive? Ther Adv Med Oncol. 2012;4(6):321–7.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91(6):699–704.PubMedCrossRefGoogle Scholar
  73. 73.
    Johnston SJ, Kenny FS, Syed BM, Robertson JF, Pinder SE, Winterbottom L, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol. 2012;23(9):2296–300.PubMedCrossRefGoogle Scholar
  74. 74.
    Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review. Br J Cancer. 2007;96(7):1025–9.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Riseberg D. Treating elderly patients with hormone receptor-positive advanced breast cancer. Clin Med Insights Oncol. 2015;9:65–73.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421–32 e8.PubMedCrossRefGoogle Scholar
  77. 77.
    Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18(3):333–45.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.PubMedGoogle Scholar
  79. 79.
    Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;167(3):659–69.PubMedCrossRefGoogle Scholar
  80. 80.
    Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.PubMedCrossRefGoogle Scholar
  81. 81.
    Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefGoogle Scholar
  83. 83.
    Early Breast Cancer Trialists’ Collaborative Group, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefGoogle Scholar
  84. 84.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Nichol AM, Chan EK, Lucas S, Smith SL, Gondara L, Speers C, et al. The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. Int J Radiat Oncol Biol Phys. 2017;98(4):829–39.PubMedCrossRefGoogle Scholar
  86. 86.
    Chesney TR, Yin JX, Rajaee N, Tricco AC, Fyles AW, Acuna SA, et al. Tamoxifen with radiotherapy compared with tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: a systematic review and meta-analysis. Radiother Oncol. 2017;123(1):1–9.PubMedCrossRefGoogle Scholar
  87. 87.
    National Comprehensive Cancer Network. Breast cancer version 2.2017 clinical practice guidelines in oncology. Available from:
  88. 88.
    Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006;24(30):4901–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.CrossRefGoogle Scholar
  90. 90.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.CrossRefGoogle Scholar
  91. 91.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603–13.PubMedCrossRefGoogle Scholar
  92. 92.
    Palussiere J, Henriques C, Mauriac L, Asad-Syed M, Valentin F, Brouste V, et al. Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomes. Radiology. 2012;264(2):597–605.PubMedCrossRefGoogle Scholar
  93. 93.
    Littrup PJ, Jallad B, Chandiwala-Mody P, D’Agostini M, Adam BA, Bouwman D. Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Interv Radiol. 2009;20(10):1329–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Soley Bayraktar
    • 1
  • Adnan Aydiner
    • 2
  1. 1.Memorial Cancer Center, Piyalepaşa Bulvarı, Okmeydanı/ŞişliIstanbulTurkey
  2. 2.Oncology Institute, Istanbul Medical FacultyIstanbul UniversityIstanbulTurkey

Personalised recommendations